Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

prizloncabtagene autoleucel

A preparation of autologous T lymphocytes engineered to express a second-generation chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, prizloncabtagene autoleucel targets and binds to CD19- and CD20-expressing tumor B cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD19/anti-CD20 CAR T cells EXP039
autologous anti-CD19/CD20 CAR-T cells C-CAR039
autologous CD19/CD20-targeting CAR T cells EXP039
autologous CD19/CD20-targeting CAR-T cells EXP039
Code name:C CAR039
C-CAR039
CCAR039
EXP 039
EXP-039
EXP039
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search